CYTOMX THERAPEUTICS INC. - COMMON STOCK

CytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer

06 يوليو 2022 15:05:00 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics Announces New Employment Inducement Grants

16 يونيو 2022 07:00:01 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics to Present at Jefferies 2022 Global Healthcare Conference

01 يونيو 2022 07:00:01 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors

26 مايو 2022 07:00:00 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

05 مايو 2022 15:15:00 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022

28 أبريل 2022 07:00:02 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors

14 أبريل 2022 15:15:00 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of Directors

23 مارس 2022 15:15:00 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics to Present Updated Preclinical Data for Conditionally Activated Cytokine Program at AACR Annual Meeting 2022

17 مارس 2022 07:00:01 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Business Update

01 مارس 2022 15:15:00 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics to Present at Cowen 42nd Annual Healthcare Conference

28 فبراير 2022 07:00:01 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

22 فبراير 2022 07:00:02 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics Announces New Employment Inducement Grants

16 فبراير 2022 07:00:01 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics Announces Promotion of Amy C. Peterson, M.D. to President and Chief Operating Officer

07 فبراير 2022 08:00:01 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid Tumors

19 يناير 2022 07:00:01 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

05 يناير 2022 07:00:03 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics Announces Preliminary Results for Ongoing Phase 2 Expansion Study of CX-2029, a First-in-Class Antibody-Drug Conjugate Candidate Targeting the Transferrin Receptor, CD71

20 ديسمبر 2021 15:05:00 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics to Present at Upcoming November Investor Conferences

11 نوفمبر 2021 07:00:01 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update

04 نوفمبر 2021 15:15:01 بحسب Nasdaq GlobeNewswire

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Cytokine Platform at Society for Immunotherapy of Cancer Annual Meeting

01 نوفمبر 2021 07:00:01 بحسب Nasdaq GlobeNewswire